tiprankstipranks
Zymeworks Inc (DE:ZA8)
FRANKFURT:ZA8
Germany Market

Zymeworks (ZA8) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

ZA8 Analyst Ratings

Strong Buy
9Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Zymeworks
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ZA8 Stock 12 Month Forecast

Average Price Target

€35.17
▲(77.45% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Zymeworks in the last 3 months. The average price target is €35.17 with a high forecast of €47.18 and a low forecast of €27.45. The average price target represents a 77.45% change from the last price of €19.82.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"€9","48":"€48","18.75":"€18.75","28.5":"€28.5","38.25":"€38.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":47.1795225,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€47.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.1701895,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€35.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.449904,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€27.45</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,18.75,28.5,38.25,48],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.265,21.41227096153846,23.55954192307692,25.706812884615385,27.854083846153845,30.001354807692305,32.14862576923077,34.29589673076923,36.44316769230769,38.59043865384615,40.73770961538461,42.88498057692307,45.03225153846154,{"y":47.1795225,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.265,20.488476115384614,21.71195223076923,22.935428346153845,24.158904461538462,25.382380576923076,26.60585669230769,27.829332807692307,29.052808923076924,30.276285038461538,31.49976115384615,32.723237269230765,33.94671338461538,{"y":35.1701895,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.265,19.894608,20.524216,21.153824,21.783432,22.413040000000002,23.042648,23.672256,24.301864000000002,24.931472,25.56108,26.190688,26.820296,{"y":27.449904,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.6,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.1,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.25,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.94,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.3,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.265,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€47.18Average Price Target€35.17Lowest Price Target€27.45
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:ZA8
H.C. Wainwright
H.C. Wainwright
€43.75€47.18
Buy
138.04%
Upside
Reiterated
08/26/26
Zymeworks price target raised to $55 from $51 at H.C. WainwrightZymeworks price target raised to $55 from $51 at H.C. Wainwright
Citi
€31.74€32.6
Buy
64.46%
Upside
Reiterated
08/26/26
Zymeworks price target raised to $38 from $37 at CitiZymeworks price target raised to $38 from $37 at Citi
Bloom Burton Analyst forecast on DE:ZA8
Bloom Burton
Bloom Burton
€30.88€31.74
Buy
60.14%
Upside
Reiterated
08/26/26
Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME), Revolution Medicines (NASDAQ: RVMD) and Agilent (NYSE: A)
Wells Fargo
€34.31
Buy
73.12%
Upside
Assigned
08/25/26
Analysts Are Bullish on These Healthcare Stocks: Zymeworks (ZYME), Johnson & Johnson (JNJ)
LifeSci Capital Analyst forecast on DE:ZA8
LifeSci Capital
LifeSci Capital
€29.17
Buy
47.15%
Upside
Reiterated
08/25/26
Analysts Are Bullish on These Healthcare Stocks: Zymeworks (ZYME), Jazz Pharmaceuticals (JAZZ)
Truist Financial Analyst forecast on DE:ZA8
Truist Financial
Truist Financial
€27.45
Buy
38.50%
Upside
Reiterated
08/11/26
Truist Financial Keeps Their Buy Rating on Zymeworks (ZYME)
Stifel Nicolaus Analyst forecast on DE:ZA8
Stifel Nicolaus
Stifel Nicolaus
€39.46
Buy
99.09%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME) and Edgewise Therapeutics (NASDAQ: EWTX)
B. Riley Securities Analyst forecast on DE:ZA8
B. Riley Securities
B. Riley Securities
€34.31€37.74
Buy
90.43%
Upside
Reiterated
08/10/26
Zymeworks price target raised to $44 from $40 at B. RileyZymeworks price target raised to $44 from $40 at B. Riley
Jefferies Analyst forecast on DE:ZA8
Unknown Analyst
Jefferies
Not Ranked
Jefferies
€36.89
Buy
86.10%
Upside
Reiterated
06/30/26
Jefferies Sticks to Their Buy Rating for Zymeworks (ZYME)
TD Cowen Analyst forecast on DE:ZA8
TD Cowen
TD Cowen
Buy
Reiterated
05/08/26
Zymeworks: Strong Ziihera Royalty Momentum and Deep Oncology Pipeline Underpin Buy Rating and Favorable Risk-Reward
Evercore ISI Analyst forecast on DE:ZA8
Evercore ISI
Evercore ISI
€28.31€41.17
Buy
107.74%
Upside
Reiterated
03/09/26
Evercore ISI Sticks to Its Buy Rating for Zymeworks (ZYME)
J.P. Morgan Analyst forecast on DE:ZA8
J.P. Morgan
J.P. Morgan
Buy
Reiterated
03/03/26
Zymeworks: Strengthened Liquidity and Preserved Zanidatamab Royalty Upside Support Overweight Rating
Citizens JMP Analyst forecast on DE:ZA8
Citizens JMP
Citizens JMP
€27.45
Buy
38.50%
Upside
Initiated
12/03/25
Zymeworks initiated with an Outperform at Citizens JMPZymeworks initiated with an Outperform at Citizens JMP
Leerink Partners Analyst forecast on DE:ZA8
Leerink Partners
Leerink Partners
€31.74€34.31
Buy
73.12%
Upside
Reiterated
11/19/25
Zymeworks price target raised to $37 from $24 at LeerinkZymeworks price target raised to $37 from $24 at Leerink
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on DE:ZA8
H.C. Wainwright
H.C. Wainwright
€43.75€47.18
Buy
138.04%
Upside
Reiterated
08/26/26
Zymeworks price target raised to $55 from $51 at H.C. WainwrightZymeworks price target raised to $55 from $51 at H.C. Wainwright
Citi
€31.74€32.6
Buy
64.46%
Upside
Reiterated
08/26/26
Zymeworks price target raised to $38 from $37 at CitiZymeworks price target raised to $38 from $37 at Citi
Bloom Burton Analyst forecast on DE:ZA8
Bloom Burton
Bloom Burton
€30.88€31.74
Buy
60.14%
Upside
Reiterated
08/26/26
Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME), Revolution Medicines (NASDAQ: RVMD) and Agilent (NYSE: A)
Wells Fargo
€34.31
Buy
73.12%
Upside
Assigned
08/25/26
Analysts Are Bullish on These Healthcare Stocks: Zymeworks (ZYME), Johnson & Johnson (JNJ)
LifeSci Capital Analyst forecast on DE:ZA8
LifeSci Capital
LifeSci Capital
€29.17
Buy
47.15%
Upside
Reiterated
08/25/26
Analysts Are Bullish on These Healthcare Stocks: Zymeworks (ZYME), Jazz Pharmaceuticals (JAZZ)
Truist Financial Analyst forecast on DE:ZA8
Truist Financial
Truist Financial
€27.45
Buy
38.50%
Upside
Reiterated
08/11/26
Truist Financial Keeps Their Buy Rating on Zymeworks (ZYME)
Stifel Nicolaus Analyst forecast on DE:ZA8
Stifel Nicolaus
Stifel Nicolaus
€39.46
Buy
99.09%
Upside
Reiterated
08/11/26
Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME) and Edgewise Therapeutics (NASDAQ: EWTX)
B. Riley Securities Analyst forecast on DE:ZA8
B. Riley Securities
B. Riley Securities
€34.31€37.74
Buy
90.43%
Upside
Reiterated
08/10/26
Zymeworks price target raised to $44 from $40 at B. RileyZymeworks price target raised to $44 from $40 at B. Riley
Jefferies Analyst forecast on DE:ZA8
Unknown Analyst
Jefferies
Not Ranked
Jefferies
€36.89
Buy
86.10%
Upside
Reiterated
06/30/26
Jefferies Sticks to Their Buy Rating for Zymeworks (ZYME)
TD Cowen Analyst forecast on DE:ZA8
TD Cowen
TD Cowen
Buy
Reiterated
05/08/26
Zymeworks: Strong Ziihera Royalty Momentum and Deep Oncology Pipeline Underpin Buy Rating and Favorable Risk-Reward
Evercore ISI Analyst forecast on DE:ZA8
Evercore ISI
Evercore ISI
€28.31€41.17
Buy
107.74%
Upside
Reiterated
03/09/26
Evercore ISI Sticks to Its Buy Rating for Zymeworks (ZYME)
J.P. Morgan Analyst forecast on DE:ZA8
J.P. Morgan
J.P. Morgan
Buy
Reiterated
03/03/26
Zymeworks: Strengthened Liquidity and Preserved Zanidatamab Royalty Upside Support Overweight Rating
Citizens JMP Analyst forecast on DE:ZA8
Citizens JMP
Citizens JMP
€27.45
Buy
38.50%
Upside
Initiated
12/03/25
Zymeworks initiated with an Outperform at Citizens JMPZymeworks initiated with an Outperform at Citizens JMP
Leerink Partners Analyst forecast on DE:ZA8
Leerink Partners
Leerink Partners
€31.74€34.31
Buy
73.12%
Upside
Reiterated
11/19/25
Zymeworks price target raised to $37 from $24 at LeerinkZymeworks price target raised to $37 from $24 at Leerink
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
REPLReplimune Group
RYTMRhythm Pharmaceuticals
VKTXViking Therapeutics
ARWRArrowhead Pharmaceuticals
EHCEncompass Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zymeworks

3 Months
Charles ZhuLifeSci Capital
Success Rate
13/16 ratings generated profit
81%
Average Return
+17.97%
Copying Charles Zhu's trades and holding each position for 3 Months would result in 81.25% of your transactions generating a profit, with an average return of +17.97% per trade.
1 Year
Charles ZhuLifeSci Capital
Success Rate
16/16 ratings generated profit
100%
Average Return
+54.57%
Copying Charles Zhu's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +54.57% per trade.
2 Years
Success Rate
16/16 ratings generated profit
100%
Average Return
+82.21%
Copying Yigal Nochomovitz's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +82.21% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZA8 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
11
11
9
5
12
Buy
7
10
15
14
17
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
21
24
19
29
In the current month, ZA8 has received 29 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ZA8 average Analyst price target in the past 3 months is 35.17.
Each month's total comprises the sum of three months' worth of ratings.

ZA8 Financial Forecast

ZA8 Earnings Forecast

Next quarter’s earnings estimate for ZA8 is €2.12 with a range of -€0.49 to €2.90. The previous quarter’s EPS was -€0.53. ZA8 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ZA8 has Performed in-line its overall industry.
Next quarter’s earnings estimate for ZA8 is €2.12 with a range of -€0.49 to €2.90. The previous quarter’s EPS was -€0.53. ZA8 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ZA8 has Performed in-line its overall industry.

ZA8 Sales Forecast

Next quarter’s sales forecast for ZA8 is €198.62M with a range of €3.57M to €237.36M. The previous quarter’s sales results were €3.93M. ZA8 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ZA8 has Performed in-line its overall industry.
Next quarter’s sales forecast for ZA8 is €198.62M with a range of €3.57M to €237.36M. The previous quarter’s sales results were €3.93M. ZA8 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ZA8 has Performed in-line its overall industry.

ZA8 Stock Forecast FAQ

What is DE:ZA8’s average 12-month price target, according to analysts?
Based on analyst ratings, Zymeworks Inc’s 12-month average price target is 35.17.
    What is DE:ZA8’s upside potential, based on the analysts’ average price target?
    Zymeworks Inc has 77.45% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Zymeworks Inc a Buy, Sell or Hold?
          Zymeworks Inc has a consensus rating of Strong Buy, which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Zymeworks Inc’s share price target?
            The average share price target for Zymeworks Inc is 35.17. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €47.18 ,and the lowest forecast is €27.45. The average share price target represents 77.45% Increase from the current price of €19.82.
              What do analysts say about Zymeworks Inc?
              Zymeworks Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of Zymeworks Inc?
                To buy shares of DE:ZA8, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.